Stock RSLS RESHAPE LIFESCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.2549 USD +1.92% Intraday chart for ReShape Lifesciences Inc. +35.59% +2.08%
May. 15 ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 15 Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M
MT
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System
MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System
CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex
CI
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX
CI
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M
MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System
CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q2 Revenue $2.3M, vs. Street Est of $2.6M
MT
ReShape Lifesciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Reshape Lifesciences Inc. Signs Preferred Partner Agreement with Hive Medical for Lead Optimization Software
CI
ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting
CI
ReShape Lifesciences Files US FDA Premarket Approval Supplement Application for Lap-Band 2.0; Shares Surge After Hours
MT
ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
CI
ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $2.3M, vs. Street Est of $2.51M
MT
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
North American Morning Briefing : Subdued Open -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RSLS Stock
  4. News ReShape Lifesciences Inc.
  5. Highlights